These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 34801029)

  • 1. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
    Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
    Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib.
    Chen T; Song C; Liang G; Xu X; Wang C; Zhang Z; Tang M
    Dis Markers; 2022; 2022():5879137. PubMed ID: 35356064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
    Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
    Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of prognostic nutritional index and its variations in advanced non-small-cell lung cancer patients treated with anlotinib monotherapy.
    Chen T; Liang G; Xiang Z; He J; Xu X; Tang M
    J Clin Lab Anal; 2022 Apr; 36(4):e24300. PubMed ID: 35179795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.
    Chi PD; Liu W; Chen H; Zhang JP; Lin Y; Zheng X; Liu W; Dai S
    PLoS One; 2014; 9(3):e91080. PubMed ID: 24625581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
    Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
    Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yu G; Shen Y; Xu X; Zhong F
    PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
    Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of
    Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
    Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
    JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
    Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
    J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
    Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
    Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
    Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
    Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
    Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
    Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients.
    Liu T; Zhou T; Luo F; Yang Y; Zhao S; Huang Y; Zhao H; Zhang L; Zhao Y
    Cancer Control; 2021; 28():10732748211028257. PubMed ID: 34184581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
    Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
    Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
    [No Abstract]   [Full Text] [Related]  

  • 20. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.